Northern Trust Corp Grows Position in Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL)

Northern Trust Corp grew its stake in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 78.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,902 shares of the company’s stock after buying an additional 17,066 shares during the period. Northern Trust Corp owned 0.48% of Cryo-Cell International worth $288,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CCEL. Rowlandmiller & PARTNERS.ADV acquired a new stake in shares of Cryo-Cell International during the fourth quarter worth $107,000. CreativeOne Wealth LLC acquired a new stake in shares of Cryo-Cell International during the fourth quarter worth $113,000. Heron Bay Capital Management acquired a new stake in shares of Cryo-Cell International during the fourth quarter worth $235,000. Finally, Topline Capital Management LLC acquired a new stake in shares of Cryo-Cell International during the fourth quarter worth $354,000. Hedge funds and other institutional investors own 10.44% of the company’s stock.

Cryo-Cell International Stock Performance

Shares of NYSEAMERICAN CCEL opened at $5.11 on Monday. Cryo-Cell International, Inc. has a 1 year low of $4.75 and a 1 year high of $9.43. The stock has a market capitalization of $41.19 million, a price-to-earnings ratio of -4.82 and a beta of 0.53. The stock’s 50-day simple moving average is $5.42.

Cryo-Cell International Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Wednesday, May 21st were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 11.74%. Cryo-Cell International’s dividend payout ratio is currently -94.34%.

Wall Street Analyst Weigh In

Separately, Maxim Group reduced their target price on Cryo-Cell International from $9.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, March 4th.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.